<DOC>
	<DOCNO>NCT02620306</DOCNO>
	<brief_summary>The purpose study evaluate Efficacy Safety Fimasartan patient hypertensive diabetic chronic kidney disease .</brief_summary>
	<brief_title>A Randomized , Double-blind , Active Control , Parallel Group , Titration , Multicenter Study Evaluate Efficacy Safety Fimasartan</brief_title>
	<detailed_description>The randomized subject take investigational product ( Fimasartan Losartan ) correspond treatment group 24 week . After , subject take Fimasartan additional 120 week open-label , 2-parallel group study conduct 2 group accordance blood pressure control criterion .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>1 . Male female adult age 19 70 year 2 . Blood pressure : Mean blood pressure screening . For treatmentnaïve patient : 140 mmHg ≤ SBP &lt; 180 mmHg DBP &lt; 110 mmHg For patient take ACEI ARB : 130 mmHg ≤ SBP &lt; 180 mmHg DBP &lt; 110 mmHg 3. eGFR : ≥ 30 ml/min/1.73 m2 within past 6 month 4 . Albuminuria ( ACR ) excretion volume ≥ 300 mg/g ( mg/day ) within past 6 month 5 . Patients diabetes 6 . Voluntarily provide write consent participate 7 . Able understand study , cooperative execution study 1 . Severe hypertension mean SBP ≥ 180 mmHg DBP ≥ 110 mmHg 2 . Orthostatic hypotension symptom 3 . Insulin dependent diabetes mellitus uncontrolled diabetes mellitus 4 . Patients dialysis , patient clinically significant cardiac hepatic disease</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>